Cargando…

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

[Image: see text] Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough Therapy Designation, for the treatment of schizophrenia. TAAR1 is a G-protein-coupled receptor (GPCR) that is e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heffernan, Michele L. R., Herman, Lee W., Brown, Scott, Jones, Philip G., Shao, Liming, Hewitt, Michael C., Campbell, John E., Dedic, Nina, Hopkins, Seth C., Koblan, Kenneth S., Xie, Linghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762745/ https://www.ncbi.nlm.nih.gov/pubmed/35047111 http://dx.doi.org/10.1021/acsmedchemlett.1c00527

Ejemplares similares

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
por: Achtyes, Eric D., et al.
Publicado: (2023)

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
por: Xiao, Guangqing, et al.
Publicado: (2022)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS
por: Hopkins, Seth C., et al.
Publicado: (2021)

Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans
por: Hopkins, Seth C., et al.
Publicado: (2021)

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
por: Ågren, Richard, et al.
Publicado: (2023)

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
por: Dedic, Nina, et al.
Publicado: (2021)

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy
por: Perini, Francesca, et al.
Publicado: (2023)

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia
por: Tsukada, Hironobu, et al.
Publicado: (2023)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
por: Chen, Yu-Luan, et al.
Publicado: (2023)

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT(1A) Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders
por: Kuvarzin, Savelii R., et al.
Publicado: (2023)

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment
por: Wang, Yunjie, et al.
Publicado: (2023)

Structural and Functional Evolution of the Trace Amine-Associated Receptors TAAR3, TAAR4 and TAAR5 in Primates
por: Stäubert, Claudia, et al.
Publicado: (2010)

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP-363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia
por: Hopkins, Seth C, et al.
Publicado: (2018)

Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP- 363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)
por: Hopkins, Seth, et al.
Publicado: (2018)

Identification and characterization of cichlid TAAR genes and comparison with other teleost TAAR repertoires
por: Azzouzi, Naoual, et al.
Publicado: (2015)

M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856
por: Milanovic, Snezana, et al.
Publicado: (2020)

Search for Structural Basis of Interactions of Biogenic Amines with Human TAAR1 and TAAR6 Receptors
por: Glyakina, Anna V., et al.
Publicado: (2021)

Analysis of Human TAAR8 and Murine Taar8b Mediated Signaling Pathways and Expression Profile
por: Mühlhaus, Jessica, et al.
Publicado: (2014)

Taare Zameen Par and dyslexic savants
por: Chakravarty, Ambar
Publicado: (2009)

Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397
por: Espinoza, Stefano, et al.
Publicado: (2018)

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice
por: Ren, Xia, et al.
Publicado: (2022)

Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays
por: Cichero, Elena, et al.
Publicado: (2023)

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects
por: Tsukada, Hironobu, et al.
Publicado: (2023)

Dynamic Stability of Volatile Organic Compounds in Respiratory Air in Schizophrenic Patients and Its Potential Predicting Efficacy of TAAR Agonists
por: Held, Anna, et al.
Publicado: (2023)

TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg
por: Liu, Jian-Feng, et al.
Publicado: (2018)

Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies
por: Francesconi, Valeria, et al.
Publicado: (2020)

New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection
por: Bellusci, Lorenza, et al.
Publicado: (2017)

Behavioral Effects of a Potential Novel TAAR1 Antagonist
por: Lam, Vincent M., et al.
Publicado: (2018)

Improving Efficiency and Equity in Early Autism Evaluations: The (S)TAAR Model
por: Brinster, Meredith I., et al.
Publicado: (2022)

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D(2)-Based Pharmacological Class Effect Query Defined by FAERS
por: Hopkins, Seth C., et al.
Publicado: (2022)

Investigation of Naturally Occurring Single-Nucleotide Variants in Human TAAR1
por: Mühlhaus, Jessica, et al.
Publicado: (2017)

The Case for TAAR1 as a Modulator of Central Nervous System Function
por: Rutigliano, Grazia, et al.
Publicado: (2018)

Review and Meta-Analyses of TAAR1 Expression in the Immune System and Cancers
por: Fleischer, Lisa M., et al.
Publicado: (2018)

Human Trace Amine-Associated Receptor TAAR5 Can Be Activated by Trimethylamine
por: Wallrabenstein, Ivonne, et al.
Publicado: (2013)

Trace Amine Associated Receptor 1 (TAAR1) Modulation of Food Reward
por: Moore, Catherine F., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_iu3hrcr28jsdljjvghqnbf8098